TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview

TCR2 Therapeutics

08/05/2023 19:37

* TCR2 Therapeutics Inc  TCRR.OQ   TCRR.O  is expected
to show no
change in quarterly revenue when it reports  results on May 10
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for TCR2 Therapeutics
Inc is
for a loss of 68 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $2​, above​ its last closing price of $1.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.78       -0.79      -1.56     Missed  -97.2
 Sep. 30 2022  -0.84       -0.83      -0.79     Beat    5.4
 Jun. 30 2022  -0.79       -0.79      -0.82     Missed  -3.8​
 Mar. 31 2022  -0.74       -0.74      -0.76     Missed  -2.1
 ​​Dec.        -0.74       -0.75      -0.72     Beat    3.9
 31 2021                                                
 Sep. 30 2021  -0.69       -0.65      -0.69     Missed  -6.3​
 Jun. 30 2021  -0.61       -0.59      -0.64     Missed  -8.8
 Mar. 31 2021  -0.53       -0.53      -0.58     Missed  -10.4
 This summary was machine generated May 8 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated